Endothelin-1 promotes tumorigenesis by modulating mitogenesis, apoptosis, angiogenesis, and metastasis, highlighting endothelin receptor antagonism as a potential adjuvant therapeutic strategy.
Endothelin-1 is a small vasoconstrictor peptide that was first identified in 1988. Here we review the evidence implicating ET-1 in tumorigenesis. In particular, we concentrate on the role of ET-1 in mitogenesis, apoptosis, angiogenesis, tumour invasion and metastasis, and discuss the potential for endothelin-system modulation as an adjuvant therapeutic strategy.
Grant et al. (Wed,) conducted a review in Cancer. Endothelin-1 was evaluated. Endothelin-1 promotes tumorigenesis by modulating mitogenesis, apoptosis, angiogenesis, and metastasis, highlighting endothelin receptor antagonism as a potential adjuvant therapeutic strategy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: